Advocacy intelligence hub — real-time data for patient organizations
Guangdong Hengrui Pharmaceutical Co., Ltd — PHASE1
Assiut University
Assiut University
Wayrilz: FDA approved
treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
Al-Mustansiriyah University — PHASE4
Shandong University — PHASE2, PHASE3
China Immunotech (Beijing) Biotechnology Co., Ltd. — PHASE1
Peking University People's Hospital
Sohag University — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance5
Patient Assistance Programs3
Wayrilz
(rilzabrutinib)Orphan drugGenzyme Corporation (A Sanofi Company)
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Rilzabrutinib is a small-molecule, covalent, reversible kinase inhibitor targeting Bruton's tyrosine kinase (BTK). Rilzabruti...
Nplate
(ROMIPLOSTIM)Orphan drugAmgen, Inc
Thrombopoietin Receptor Agonist [EPC]
12.1 Mechanism of Action Nplate increases platelet production through binding and activation of the TPO receptor, a mechanism analogous to endogenous ...
WinRho SD
(Rho (D) immune globulin intravenous (human))Orphan drugRh Pharmaceuticals, Inc.
Eltrombopag
(ELTROMBOPAG OLAMINE)Orphan drugstandardNovadoz Pharmaceuticals LLC
Dyural 80-Lm
(METHYLPREDNISOLONE ACETATE, LIDOCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE, POVIDINE IODINE, ISOPROPYL ALCOHOL)Orphan drugstandardAdvanced Rx Pharmacy of Tennessee, LLC
12.1 Mechanism of Action Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical...
ELTROMBOPAG
(ELTROMBOPAG)standardDr. Reddy's Laboratories Inc.,
12.1 Mechanism of Action Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as c...
Doptelet
(avatrombopag)Orphan drugstandardSobi, Inc.
12.1 Mechanism of Action Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation...
Clinical Characteristics and Predictors of Chronicity in Children With Immune Thrombocytopenia.
Introduction Immune thrombocytopenia (ITP) in children is typically self-limited; however, a subset progresses to chronic disease. Identifying early predictors of chronic evolution remains clinically ...
The association between immature platelet count and clinical characteristics in pediatric immune thrombocytopenia.
Despite the increasing number of treatments for immune thrombocytopenia (ITP), there are no established laboratory predictors of treatment response. Immature platelet fraction (IPF) and immature plate...
Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
Current second-line treatments for immune thrombocytopenia (ITP) require long-term administration. Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line t...
Thrombosis in immune thrombocytopenia.
Patients with immune thrombocytopenia (ITP) have a higher thrombotic rate than the general population, and certain ITP treatments may further increase this risk. This narrative 'In a Nutshell' review ...
The humoral pathophysiology of immune thrombocytopenia: How close are we to patient-specific disease treatment?
Primary immune thrombocytopenia (ITP) is an autoimmune disease in which soluble humoral immune factors, especially anti-platelet autoantibodies, can drive thrombocytopenia by accelerating platelet cle...
Navigating the Hemostatic Balance: Anticoagulation and Antiplatelet Therapy in Patients with Thrombocytopenia.
Background: Thrombocytopenia is traditionally perceived as a bleeding-predominant condition; however, growing evidence indicates that many thrombocytopenic states are paradoxically associated with an ...
Abdulgabar Salama, MD
Universitätsklinikum Charite, Med. Fakultät der Humboldt-Universität Berlin
Lei Zhang, MD
Blood disease hospital, Chinese academy of medical sciences
Wolfgang Frenzel, MD
International Medical Director
Ming Hou, PhD
Qilu Hospital of Shandong University
lei zhang, MD
Chinese Academy of Medical Science and Blood Disease Hospital
Charlotte Bradbury
Centre for Trials Research College of Biomedical & Life Sciences Cardiff University